biOasis Announces the Release of an Analyst Report
(firmenpresse) - VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 01/20/15 -- biOasis Technologies Inc. (TSX VENTURE: BTI)(OTCQX: BIOAF)(the "Company") wishes to announce the release of an analyst report (the "Report") providing a synopsis of the Company. Mr. Jim Darcel, , prepared the Report.
The Company cautions its investors, shareholders and other parties that any opinions, estimates or forecasts regarding the Company''s performance made by Mr. Darcel are his alone and do not represent opinions, forecasts or predictions of the Company or its management. The Company does not by its reference above or distribution imply its endorsement of, or concurrence with such information, conclusions or recommendations.
About biOasis
biOasis Technologies Inc. is a biopharmaceutical company headquartered in Vancouver, Canada. Based on Transcend, biOasis proprietary brain delivery platform, the company is focused on creating a drug delivery platform that can transport drugs across the blood-brain barrier to address unmet medical needs in the treatment of brain diseases such as neurodegenerative diseases, metastatic brain cancers and metabolic diseases. biOasis trades on the OTCQX under the symbol "BIOAF" and on the TSX Venture Exchange under the symbol "BTI". For more information about the company please visit .
Forward Looking Statements
Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at . Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.
On Behalf of the Board of Directors
Rob Hutchison Chairman & CEO
"Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release"
Contacts:
biOasis Technologies Inc.
Tiffany Tolmie
778-383-3280 x103
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 20.01.2015 - 16:24 Uhr
Sprache: Deutsch
News-ID 1331492
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
VANCOUVER, BRITISH COLUMBIA
Phone:
Kategorie:
Medical Devices
Anmerkungen:
Diese Pressemitteilung wurde bisher 184 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"biOasis Announces the Release of an Analyst Report
"
steht unter der journalistisch-redaktionellen Verantwortung von
biOasis Technologies Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
